Tehran (IP) - Head of the Food and Drug Administration of Iran said that the medicine for the treatment of patients with Spinal Muscular Atrophy (SMA) will be developed in Iran for the first time this year.

Iran PressIran News: SMA is an inherited disease that affects nerves and muscles, causing muscles to become increasingly weak.

SMA is a genetic condition that causes muscle weakness and atrophy (when muscles get smaller).

SMA can affect children's ability to crawl, walk, sit up, and control head movements.

Severe SMA can damage the muscles used for breathing and swallowing.

According to the Ministry of Health, 500 patients have been identified in the country, and the amount of medication used by these patients is based on their weight.

Bahram Daraei, the Head of the Food and Drug Administration of Iran, said that the government is trying to provide medicine for Special Diseases this year without any problems, adding: "Five domestic manufacturers produce these drugs, but the import of drugs is also on the agenda."


Read More:

Iran exports 4 million doses of corona vaccine

WHO: Registration of Iranian COVID vaccines to be expedited